Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nacystelyn chronic dosing study in moderate to severe COPD
2019-001160-29Phase 2Completed
- Sponsor
- SMB Laboratoires
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of nacystelyn in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by SMB Laboratoires. Primary endpoint: Change in airway geometry by Functional Respiratory Imaging. Started May 2019; status: completed.
02
Drugs
nacystelyn
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-001160-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001160-29.